FDA to quickly review Roche's chemo-free lung cancer regimen

Roche’s challenge to Merck & Co’s immunotherapy Keytruda in first line lung cancer has gathered momentum after the FDA agreed to a fast review of Tecentriq monotherapy, preventing the n

Trial answers the KRAS question for Keytruda in lung cancer

Roche steps up Merck challenge with first-line NSCLC approva...

FDA sets January action date for Keytruda in early bladder c...

The best-selling drugs of the next 5 years

Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling dru

Merck, Eisai get triple approvals for Keytruda/Lenvima combi...